Hosted on MSN

Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions

“This is an exciting day as it represents our first analyst call reporting on our first ever quarter or, more accurately, partial quarter of sales since the commercial launch of CARDAMYST for acute ...
Business Insider

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

ReVeRA-301Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose ...
Yahoo Finance

Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Finanznachrichten

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with ...

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose ...